UK MHRA aims to reduce anonymised patient reports sent to companies
This article was originally published in SRA
Executive Summary
The UK Medicines and Healthcare products Regulatory Agency has implemented changes aimed at reducing the number of irrelevant anonymised single patient reports (ASPRs) – and their electronic equivalent, E2B individual case safety reports (ICSRs) – sent out to drug companies1.